Subscribe To
Kura oncology announces three presentations at aacr-nci-eortc international conference on molecular targets and cancer therapeutics
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, ...
October 4, 2023, 11:30 am
Mirati (mrtx) down 7% on chmp's opinion on krazati filing
Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in krasg12c mutated NSCLC does not fulfill ...
July 24, 2023, 1:05 pm
Frontier medicines presents new preclinical data on its development candidate, fmc-376, a dual krasg12c inhibitor, at the 2023 aacr annual meeting
-FMC-376 is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active and inactive forms of ...
April 16, 2023, 7:00 pm
Revolution medicines reports fourth quarter and full year 2022 financial results and update on corporate progress
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-...
February 27, 2023, 9:05 pm
Mirati's (mrtx) stock rallies 11% on buyout speculations
Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated ...
November 24, 2022, 12:02 pm
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...
February 16, 2022, 8:21 am
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...
February 16, 2022, 8:21 am
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...
February 16, 2022, 8:21 am
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...
January 21, 2022, 12:14 pm
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...
January 21, 2022, 12:14 pm
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...
January 21, 2022, 12:14 pm